Nasdaq

Innovent Biologics : Second Phase 3 Trial Of Mazdutide In Type 2 Diabetes Meets Study Endpoints

(RTTNews) - Innovent Biologics Inc. said that the Phase 3 clinical trial (DREAMS-1) of mazdutide, a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese ...
Healio

Mazdutide superior to dulaglutide for reducing HbA1c, body weight in type 2 diabetes

Please provide your email address to receive an email when new articles are posted on . Adults with type 2 diabetes had larger decreases in HbA1c at 28 weeks with mazdutide vs. dulaglutide. More than ...
BioWorld

Innovent’s mazdutide hits phase III endpoints in type 2 diabetes

Innovent Biologics Inc.’s glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, mazdutide, met the primary endpoint and all key secondary endpoints in a phase III type 2 ...
Nasdaq

Innovent : Phase 2 Study Of Mazdutide In Chinese Patients With Type 2 Diabetes Meets Main Goal

(RTTNews) - Innovent Biologics Inc. (IVBXF.OB) said Monday that a multi-center, randomized, double-blind, placebo and dulaglutide-controlled phase 2 study of mazdutide (IBI362) in Chinese patients ...